Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • illumina
    Registered Vendor
    • Mar 2009
    • 8

    Manager, Bioinformatics - Hayward #1863

    Why is one person more likely to develop a disease—like cancer, diabetes or Parkinson’s—than someone else? Why would one person respond differently to treatment than another? Illumina’s technologies are helping researchers around the world to answer these questions and others, on a scale not even possible a few years ago.

    Illumina is the only life sciences company developing genome-wide technologies for genotyping, gene expression and sequencing—the three cornerstones of modern genetic analysis. By enabling studies of thousands of patient samples at once, our products set genetic discovery on fast forward. And we’re just getting started.

    Manager, Bioinformatics - Hayward #1863

    Lead bioinformatics, data analysis, and algorithm development team at Illumina’s Hayward site and establish strong collaborative connections to bioinformatics and computational biology groups throughout Illumina. Reports to Chief Information Officer responsible for all corporate and scientific informatics efforts worldwide

    Job duties include but are not limited to:
    • Represent informatics issues across company as part of a leadership team internally and externally with early adopters and collaborators
    • Strategic input into planning, budgeting, project execution and milestone delivery
    • Forward thinking and innovative, able to challenge and persuade without confrontation. Driven by desire to push envelope in key areas and also back that up with concrete delivery of corporate milestones.

    Education and Experience:
    • Advanced degree in computer science, genetics, genomics, physics, chemistry, or engineering
    • 2+ years of team or project management in commercial environment.
    • Strong knowledge of sequencing informatics, algorithmic and mathematical methods in data analysis, and experimental design
    • Knowledge of database systems and annotation approaches amenable to bioinformatics application
    • Background in high throughput data management and cluster computing
    • Competency in RNA expression, uRNA, ChIP, methylation, and related scientific domains
    • Product development experience within domain of bioinformatics or scientific instrumentation
    • Proven abilities of people management

    When you join the high-performing team at Illumina, your work takes on new meaning—to an exponential degree. Our growth, our positive culture, and the impact our products are having in the world ignite a passion that drives our people forward. And together, we accomplish beyond expectations.

    experience the power of i
    www.illumina.com/careers
    Last edited by illumina; 11-18-2009, 10:03 AM.

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
29 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-23-2026, 11:41 AM
0 responses
21 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
212 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
78 views
0 reactions
Last Post SEQadmin2  
Working...